Private equity faces increasing scrutiny from antitrust authorities. Recently, the Federal Trade Commission sued a large financial sponsor and its portfolio company over a long series of acquisitions that allegedly consolidated Texas anesthesia markets and sharply raised prices. As the transactions span ten years, a natural question arises as to how they escaped enforcement for so long. Our answer is that the agency did not challenge the acquisitions in their incipiency because they were exempt
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.145.108.43
Please verify email or join us to access premium content!